The goal of the SURPASS-1 trial was to evaluate the dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist tirzepatide compared with placebo among patients with type 2 diabetes.
↧